KIM
VRTX icon

Kane Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kane Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$785K Sell
1,759
-9
-0.5% -$4.2K 0.4% 53
2025
Q4 		$802K Hold
1,768
– – 0.39% 52
2025
Q3 		$692K Sell
1,768
-463
-21% -$193K 0.34% 58
2025
Q2 		$993K Sell
2,231
-89
-4% -$41K 0.52% 48
2025
Q1 		$1.12M Buy
2,320
+99
+4% +$46.1K 0.54% 37
2024
Q4 		$894K Buy
+2,221
New +$1.03M 0.5% 39

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Kane Investment Management's VRTX Position: Q1 2026 in Review

Kane Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.51% in Q1 2026, selling an estimated $4.2K and leaving 1,759 shares worth $785K. The position accounts for 0.4% of the portfolio, ranked #53.

Kane Investment Management first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.12M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Kane Investment Management held 1,759 shares of Vertex Pharmaceuticals worth $785K as of Q1 2026.
  • Kane Investment Management sold 9 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.2K.
  • Vertex Pharmaceuticals made up 0.4% of Kane Investment Management's portfolio in Q1 2026, its #53 holding.
  • Kane Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Kane Investment Management's Vertex Pharmaceuticals position peaked at $1.12M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Kane Investment Management's 13F filing for Q1 2026, filed 14 May 2026.